Concepedia

Marina D. Kaymakcalan

MD

14

Publications

882

Citations

13

H-Index

2014

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Pfizer (United States)

University of Genoa

University of Calgary

Marina D. Kaymakcalan is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and urology.

ORCID

Top concepts

Publications per year

2014–2021

14

Publications

14

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Ole‐Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin et al. · Cancer · 2014 · 202 citations · Full text

Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma

Rana R. McKay, Gustavo E. Rodriguez, Xun Lin et al. · Clinical Cancer Research · 2015 · 132 citations · Full text

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma

Aly‐Khan A. Lalani, Wanling Xie, David A. Braun et al. · European Urology Oncology · 2019 · 94 citations · Full text

, , +7

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study

André P. Fay, Sabina Signoretti, Marcella Callea et al. · Journal for ImmunoTherapy of Cancer · 2015 · 90 citations · Full text

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

Sarah Abou Alaiwi, Wanling Xie, Amin H. Nassar et al. · Journal for ImmunoTherapy of Cancer · 2020 · 82 citations · Full text

Rows per page

1–5 of 14